Tempus AI jumps 12% for 3rd straight session on cancer blood test kit launch
Tempus AI launched a new blood-based cancer detection test kit on April 15, extending a three-session winning streak. The stock has gained roughly 32.6% over three days from its April 13 open, with volume running at 2.59x the 20-day average — even as EPS revisions trended negative, signalling the market is buying the product story, not the earnings outlook.
Supporting 9 queries
To surface this insight, Baselight ran 9 queries across its structured data. Each one is reproducible — open it, read the SQL, and rerun it yourself.
Conclusion
Close: $56.41 vs open $50.35 → +12.04% (Apr 15); Volume: 12,271,847 vs 20-day avg 4,742,965 → 2.59x; 3-day run: $42.54 open Apr 13 → $56.41 close Apr 15 (+32.6%); 52-week range: $39.01–$104.32; EPS revisions: 7 downward in 7 days for current quarter; Cancer blood test kit launch confirmed by Insider Monkey, Apr 16, 2026.